The invention relates to a method of customizing a nail-biting and/or finger sucking treatment solution, and a kit for providing a nail-biting and finger sucking treatment that is customizable for a wide range of afflicted users seeking to break a persistent nail-biting and/or finger sucking habit. In exemplary embodiments, the composition kit includes two separate containers, a first container having a nail growth-promoting, waterproofing composition that may be applied directly on a user's nails; and a second container may include an additive for customizing a bitterness factor of the first composition. Typically, the first container includes an applicator such as a brush. To facilitate adding the additive in a manner that is easily customizable, the second container may include a dropper for adding small doses of the additive composition to the first composition. The customizable kit allows the user to safely adjust the bitterness so that the treatment remains effective.

The invention relates to a method of customizing a nail-biting and/or finger sucking treatment solution, and a kit for providing a nail-biting and finger sucking treatment that is customizable for a wide range of afflicted users seeking to break a persistent nail-biting and/or finger sucking habit. In exemplary embodiments, the composition kit includes two separate containers, a first container having a nail growth-promoting, waterproofing composition that may be applied directly on a user's nails; and a second container may include an additive for customizing a bitterness factor of the first composition. Typically, the first container includes an applicator such as a brush. To facilitate adding the additive in a manner that is easily customizable, the second container may include a dropper for adding small doses of the additive composition to the first composition. The customizable kit allows the user to safely adjust the bitterness so that the treatment remains effective.

A method for treating glycogen storage disease by administering an effective amount of a composition that includes ketogenic odd carbon fatty acids that ameliorate the symptoms of these diseases.

A method for treating glycogen storage disease by administering an effective amount of a composition that includes ketogenic odd carbon fatty acids that ameliorate the symptoms of these diseases.

The present disclosure provides compounds of Formula (VIA), Formula (IIIA), Formula (IVA), and Formula (VA). The compounds are prodrugs of alpha-ketoglutarate, alpha-ketobutryrate, alpha-ketoisovalerate, and alpha-ketoisohexanoate, which are useful in treating or preventing age related diseases, disorders, or conditions. ##STR00001##

The present invention relates to an inhibitor of an iron-containing hydrogenase of a methanogenic archaeon for use in the treatment or prevention of a parkinsonian condition, wherein said archaeon is in the gut of a subject and is characterized by the production of 2-hydroxypyridine. In addition, the present invention relates to a pharmaceutical composition comprising such an inhibitor and a kit comprising such an inhibitor. Further, the present invention relates to a method of screening for an inhibitor for use according to the present invention and a method for determining whether or not a subject is susceptible to a treatment with an inhibitor for use according to the present invention.

The present invention relates to an inhibitor of an iron-containing hydrogenase of a methanogenic archaeon for use in the treatment or prevention of a parkinsonian condition, wherein said archaeon is in the gut of a subject and is characterized by the production of 2-hydroxypyridine. In addition, the present invention relates to a pharmaceutical composition comprising such an inhibitor and a kit comprising such an inhibitor. Further, the present invention relates to a method of screening for an inhibitor for use according to the present invention and a method for determining whether or not a subject is susceptible to a treatment with an inhibitor for use according to the present invention.

The present invention relates to an inhibitor of an iron-containing hydrogenase of a methanogenic archaeon for use in the treatment or prevention of a parkinsonian condition, wherein said archaeon is in the gut of a subject and is characterized by the production of 2-hydroxypyridine. In addition, the present invention relates to a pharmaceutical composition comprising such an inhibitor and a kit comprising such an inhibitor. Further, the present invention relates to a method of screening for an inhibitor for use according to the present invention and a method for determining whether or not a subject is susceptible to a treatment with an inhibitor for use according to the present invention.

Methods and compositions are provided for treatment of chronic liver diseases such as NASH, for example, in order to slow disease progression, and reduce portal-systemic shunting. Methods comprising cholate liver function tests and administration of a statin and a biguanide are provided. Compositions comprising a statin and a biguanide are also provided.

Methods and compositions are provided for treatment of chronic liver diseases such as NASH, for example, in order to slow disease progression, and reduce portal-systemic shunting. Methods comprising cholate liver function tests and administration of a statin and a biguanide are provided. Compositions comprising a statin and a biguanide are also provided.